MEI Net Current Asset Value from 2010 to 2025

MEIP Stock  USD 2.43  0.03  1.22%   
MEI Pharma Net Current Asset Value yearly trend continues to be relatively stable with very little volatility. Net Current Asset Value is likely to drop to 0.00. At this time, MEI Pharma's Income Before Tax is relatively stable compared to the past year. As of 03/05/2025, Net Income is likely to grow to about 16.8 M, while Total Operating Expenses is likely to drop slightly above 31.9 M. . View All Fundamentals
 
Net Current Asset Value  
First Reported
2010-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
0.0
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MEI Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MEI Pharma's main balance sheet or income statement drivers, such as Interest Expense of 310.3 K, Selling General Administrative of 28.1 M or Total Revenue of 78.8 M, as well as many indicators such as Price To Sales Ratio of 0.32, Dividend Yield of 0.49 or PTB Ratio of 0.63. MEI financial statements analysis is a perfect complement when working with MEI Pharma Valuation or Volatility modules.
  
Check out the analysis of MEI Pharma Correlation against competitors.
To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.

Additional Tools for MEI Stock Analysis

When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.